Development of a liquid chromatography/negative-ion electrospray tandem mass spectrometry assay for the determination of cilnidipine in human plasma and its application to a bioequivalence study

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 862, Issue 1-2, 2008, Pages 246-251

  Lee, Heon Woo ^a   Seo, Ji Hyung ^a   Lee, Hyun Su ^a   Jeong, Seo Young ^a   Cho, Young Wuk ^b   Lee, Kyung Tae ^a  

^a Kyung Hee University   (South Korea)

^b Biomedical Science Institute   (South Korea)

Author keywords

Bioequivalence; Cilnidipine; Human plasma; Liquid chromatography tandem mass spectrometry; Liquid liquid extraction

Indexed keywords

METHYL-T-BUTYL ETHER (MTBE); TANDEM MASS SPECTROMETRY;

ELECTROSPRAY IONIZATION; MASS SPECTROMETRY; METHANOL; PLASMA (HUMAN);

LIQUID CHROMATOGRAPHY;

ACETIC ACID; ACETIC ACID ETHYL ESTER; AMMONIUM ACETATE; BENIDIPINE; CILNIDIPINE; CINAPIN; HEXANE; METHANOL; TERT BUTYL METHYL ETHER; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DEVELOPMENT; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG FORMULATION; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; MASS SPECTROMETRY; NEGATIVE ION ELECTROSPRAY; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

CALCIUM CHANNEL BLOCKERS; CALIBRATION; DIHYDROPYRIDINES; HUMANS; REFERENCE STANDARDS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY;

EID: 38749121268     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2007.11.016     Document Type: Article

References (18)

1. Staessen J.A., Wang J.G., and Thijs L. J. Hypertens. 21 (2003) 1055
2. Fukuo K., Yang J., and Suzuki T. Hypertens. Res. 26 (2003) 503
3. Yao K., Sato H., Sonoda R., Ina Y., Suzuki K., and Ohno T. Hypertens. Res. 26 (2003) 569
4. Umemoto S., Tanaka M., and Kawahara S. Hypertens. Res. 27 (2004) 877
5. Yamagata K., Ichinose S., and Tagami M. Hypertens. Res. 27 (2004) 271
6. Yui Y., Sumiyoshi T., and Kodama K. Hypertens. Res. 27 (2004) 181
7. Yui Y., Sumiyoshi T., and Kodama K. Hypertens. Res. 27 (2004) 449
8. Leung H.S., Yao X., Leung F.P., Ko W.H., Chen Z.Y., Gollasch M., and Huang Y. Br. J. Pharmacol. 147 (2006) 55
9. Fujii S., Kameyama K., Hosono M., Hayashi Y., and Kitamura K. J. Pharmacol. Exp. Ther. 280 (1997) 1184
10. Minami J., Ishimitsu T., Kawano Y., Numabe A., and Matsuoka H. J. Cardiovasc. Pharmacol. 32 (1998) 331
11. Minami J., Kawano Y., Makino Y., Matsuoka H., and Takishita S. Br. J. Clin. Pharmacol. 50 (2000) 615
12. Venishetty V.K., Durairaj C., Sistla R., Yamsani M.R., and Diwan P.V. Biomed. Chromatogr. 4 (2007) 363
13. Zendelovska D., Simeska S., Sibinovska O., Kostova E., Milosevska K., Jakovski K., Jovanovska E., Kikerkov I., Trojacanec J., and Zafirov D. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 839 1-2 (2006) 85
14. Hatada K., Kimura M., Ono I., and Ozaki M. J. Chromatogr. 583 (1992) 116
15. Cho S.H., Lee H.W., Im H.T., Park W.S., Choi Y.W., Rew J.H., and Lee K.T. Rapid Commun. Mass Spectrom. 20 8 (2006) 1293
16. Kang W., Yun H.Y., Liu K.H., Kwon K.I., and Shin J.G. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 805 2 (2004) 311
17. KFDA guidance for industry, statistical approaches to establishing bioequivalence, Bioequivalence Division, Pharmacology Department, National Institute of Toxicology Department, 2003, Website: http://ezdrug.kfda.go.kr/kfda2.
18. Wu Z., Gao W., Phelps M.A., Wu D., Miller D.D., and Dalton J.T. Anal. Chem. 76 (2004) 839